Tandem Diabetes reports Q3 EPS (9c), consensus (20c)
Reports Q3 revenue $94.7M, consensus $89.14M. Reports Q3 Adjusted EBITDA margin 13% vs. 10% last year. As of September 30, 2019, the company had $156.9M in cash, cash equivalents and short-term investments. This represents a $25.6M increase in the third quarter of 2019 and a $27.9M increase since December 31, 2018. CEO John Sheridan says: "Our third quarter results once again demonstrate that technology drives customer adoption, and that there is meaningful long-term opportunity to continue bringing the benefits of insulin pump therapy to people with diabetes worldwide. With approval of the t:slim X2 insulin pump with Control-IQ technology pending, we're positioned for an exciting end of 2019 and beyond as we work to continue driving growth through innovation and further our mission to improve the lives of people with diabetes."